In Willebrand disease, there is currently no test available to identify non-invasively patients with a high risk of bleeding from angiodysplasias The study propose to use a sublingual capillary bed analysis by video-microscopy, a sensitive, reproducible and non-invasive technique, to assess whether sublingual capillary density is predictive of hemorrhagic risk for patients with von Willebrand disease.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
400
Measurement of sublingual capillary density by video microscopy
Collection of citrate tubes of 5 mL at baseline and at 36 months
CHU de Lille
Lille, Nord, France
RECRUITINGarea under the ROC curve from Sublingual capillary density to inclusion for the event "existence of at least a clinically significant haemorrhage"
Time frame: at 3 years
Sublingual capillary density
To compare the sublingual capillary density of patients with von Willebrand disease to that of 3 other groups of patients: * with a severe form of hemophilia A * with a moderate form of hemophilia A * women carrying the hemophilia gene
Time frame: At baseline
qualitative abnormalities of sublingual capillaries (capillary haemorrhage, capillary dystrophy)
presence or absence of qualitative abnormalities
Time frame: At baseline and at 3 years
delta of Sublingual capillary density increase
Time frame: between inclusion and end of study (at 3 years)
ISTH-BAT haemorrhagic score (International Society on Thrombosis and Hemostasis - Bleeding Assessment Tool)
ISTH-BAT is a questionnaire minimum score ranges from 0 to 10 whereas maximum score ranges from 20 to 30
Time frame: At baseline, at 3 years
delta of increase of ISTH-BAT haemorrhagic score
ISTH-BAT is a questionnaire minimum score ranges from 0 to 10 whereas maximum score ranges from 20 to 30
Time frame: between inclusion and end of study (at 3 years)
plasma levels of proangiogenic markers
dosage of angiopoietin-1, angiopoetin-2 (pg/mL) measured by ELISA
Time frame: at inclusion and end-of-study visits(at 3 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
plasma levels of galectine
galectin-1 and galectin-3 measured by ELISA
Time frame: at inclusion and end-of-study visits(at 3 years)
plasma levels of VEGF
Concentration (pg/ml) of Vascular Endothelial Growth Factor (VEGF) in blood measured by ELISA
Time frame: at inclusion and end-of-study visits(at 3 years)
delta of increase in plasma levels of all proangiogenic markers
Time frame: At inclusion and end of study (at 3 years)